Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.
Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD).
The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD.
The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13.
Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 23 | -0.94 Decreased by -370% | -0.88 Decreased by -6.82% |
| Aug 9, 23 | -0.63 Decreased by -125% | -1.1 Increased by +42.73% |
| May 12, 23 | -0.09 Increased by +75.68% | -0.09 |
| Mar 23, 23 | -0.13 Increased by +67.5% | -0.19 Increased by +31.58% |
| Nov 10, 22 | -0.2 Increased by +37.5% | -0.28 Increased by +28.57% |
| Aug 11, 22 | -0.28 Decreased by -333.33% | -0.36 Increased by +22.22% |
| May 12, 22 | -0.37 Increased by +2.63% | -0.35 Decreased by -5.71% |
| Mar 24, 22 | -0.4 Increased by +56.04% | -0.33 Decreased by -21.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -5.86 M Increased by +26.41% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -3.92 M Increased by +65.3% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -5.59 M Increased by +62.17% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Increased by +100% | -3.88 M Increased by +80.69% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -7.96 M Increased by +36.82% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by -100% | -11.3 M Decreased by -375.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -14.78 M Decreased by -50.49% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | -18 M Decreased by N/A% | -20.1 M Decreased by -77.21% | Increased by +111.65% Decreased by N/A% |